← Back to screener

PUMA BIOTECHNOLOGY, INC. PBYI

Rank #1035 · Nasdaq · $0.5B market cap
Audited by KPMG LLP, no going-concern flag in the latest filing.
Score
54.5
P/E
24.6
P/B
24.59
ROE
99.9%
Op. Margin
13.9%
Debt Ratio
561%

Health Check — percentile rank within this universe, based on the latest annual filing

Valuation ★★☆☆☆
Weak

P/E 24.6x, P/B 24.59x. Ranks in the top 62% of the universe.

Profitability ★★★★☆
Excellent

ROE 99.9%. Ranks in the top 18% of the universe.

Safety ★☆☆☆☆
Poor

Debt ratio 561%. Ranks in the top 81% of the universe. Above 200% signals meaningful leverage risk.

Growth ★★☆☆☆
Average

Revenue growth of 3.3% year over year. Ranks in the top 55% of the universe.

Profitability is the relative strength · Safety is the relative weakness (relative to this universe).

Financials annual, from SEC 10-K filings

FYRevenueOp. IncomeNet IncomeEquityOp. Margin%Debt%
2011–$-0.0B$-0.0B$0.1B–2
2012–$-0.0B$-0.0B$0.1B–2
2013–$-0.0B$-0.0B$0.1B–42
2014–$-0.1B$-0.1B$0.1B–37
2015–$-0.1B$-0.1B$0.1B–35
2016–$-0.1B$-0.1B$0.1B–40
2017$0.0B$-0.2B$-0.2B$0.1B-867.937
2018$0.0B$-0.3B$-0.3B$0.2B-999.154
2019$0.0B$-0.3B$-0.3B$0.2B-1056.1107
2020$0.3B$-0.1B$-0.1B$0.1B-37.7408
2021$0.3B$-0.0B$-0.1B$0.0B-14.3729
2022$0.2B$-0.0B$-0.1B$0.0B-13.51312
2023$0.3B$0.0B$-0.0B$-0.0B0.5-3368
2024$0.2B$0.0B$0.0B$-0.0B10.4-7240
2025$0.2B$0.0B$0.0B$0.0B13.9561

← See the full screener